ABSTRACT-We studied the pharmacological characteristics of oxepino [4,3-b]pyridin-11-ylidene)-piperidino]propionic acid dihydrate), a novel amphoteric anti allergic agent, on the central nervous system (CNS). Its selectivity for the histamine H1-receptor and its ability to penetrate into the CNS were compared with those of typical antiallergic agents and the non amphoteric basic compound PY-608 (8-fluoro-5,11-dihydro-l l-(1-methyl-4-piperidylidene)benz [b]oxepino [4,3-b]pyridine), which has a chemical structure similar to that of HSR-609. In the in vitro study, HSR-609 had a high affinity for H1-receptors in the guinea pig cerebral cortex in comparison to affinities for mus carinic and serotonin 5-HT2-receptors in the rat cerebral cortex, while the selectivity of PY-608 for the H1 receptor was low. The inhibitory effects of these antiallergic agents on histamine-induced increase of vas cular permeability in mice (ED50) were compared with the displacement of [3H]mepyramine binding to H1 receptors in mouse brain ex vivo (ID50). The ID50/ED50 ratio of HSR-609 was much larger than those of cyproheptadine, ketotifen and PY-608 and larger than those of terfenadine and cetirizine. HSR-609 was found to display selective displacement of the [3H]mepyramine binding to H1-receptors for lung vs cerebral cortex as found with terfenadine in guinea pigs ex vivo. These findings suggest that HSR-609 has high selectivity for the H1-receptor and poor ability to penetrate into the CNS in mice and guinea pigs due to its amphoteric chemical structure.
ABSTRACT-We studied the pharmacological characteristics of HSR-609 (3-[4-(8-fluoro-5,11-dihydro benz [b] oxepino [4,3-b] pyridin-11-ylidene)-piperidino]propionic acid dihydrate), a novel amphoteric anti allergic agent, on the central nervous system (CNS). Its selectivity for the histamine H1-receptor and its ability to penetrate into the CNS were compared with those of typical antiallergic agents and the non amphoteric basic compound PY-608 (8-fluoro-5,11-dihydro-l l-(1-methyl-4-piperidylidene)benz [b] oxepino [4,3-b] pyridine), which has a chemical structure similar to that of HSR-609. In the in vitro study, HSR-609 had a high affinity for H1-receptors in the guinea pig cerebral cortex in comparison to affinities for mus carinic and serotonin 5-HT2-receptors in the rat cerebral cortex, while the selectivity of PY-608 for the H1 receptor was low. The inhibitory effects of these antiallergic agents on histamine-induced increase of vas cular permeability in mice (ED50) were compared with the displacement of [3H]mepyramine binding to H1 receptors in mouse brain ex vivo (ID50). The ID50/ED50 ratio of HSR-609 was much larger than those of cyproheptadine, ketotifen and PY-608 and larger than those of terfenadine and cetirizine. HSR-609 was found to display selective displacement of the [3H]mepyramine binding to H1-receptors for lung vs cerebral cortex as found with terfenadine in guinea pigs ex vivo. These findings suggest that HSR-609 has high selectivity for the H1-receptor and poor ability to penetrate into the CNS in mice and guinea pigs due to its amphoteric chemical structure.
Keywords: Antiallergic agent, HSR-609, Central nervous system penetration, Histamine H1-receptor, Amphoteric compound
We have synthesized many amphoteric compounds through zwitter-ionization of classical tricyclic antihista mines by conversion of N-alkyl groups into N-alkylene carboxy groups to develop non-sedative antiallergic agents with potent antihistaminic activities and have investigated the potencies of the antiallergic effects of these compounds as well as their depressant effects on the central nervous system (CNS) (1, 2) . These studies showed that the combination of zwitter-ionization and introduction of a pyridine component into the tricyclic antihistamines was important for attaining higher hydrophilicity, which was considered to be a factor in reducing penetration into the CNS (2). Our efforts finally led to a new amphoteric compound HSR-609 (3-[4-(8 fluoro-5,11-dihydrobenz[b] oxepino [4,3-b] pyridin-l 1-ylid ene)piperidino]propionic acid dihydrate) (2) (Fig. 1 ). Various pharmacological studies on mice, rats, guinea pigs and dogs have shown that HSR-609 has potent anti allergic and antihistaminic activities in vivo (2, 3) . The ability of HSR-609 to penetrate into the CNS was much lower than that of ketotifen fumarate as determined by the ex vivo displacement of [3H]mepyramine binding to histamine H1-receptors in the mouse brain in comparison with its peripheral antihistaminic effect (2) . However, the H1-receptor selectivity of HSR-609 in comparison to other receptors is yet to be evaluated, and the CNS penetrative ability of HSR-609 has not yet been compared with those of other typical antiallergic agents nor among species other than mice. Therefore, to further elucidate the pharmacological profile of HSR-609, we compared it with typical sedative antiallergic agents, cyproheptadine hydrochloride, ketotifen fumarate, azelastine hydrochlo ride and oxatomide, and also with typical non-sedative antiallergic agents, terfenadine and cetirizine dihydro chloride (4-11). The selectivity of HSR-609 for the H1-receptor was investigated by in vitro H1-receptor binding in guinea pig cerebral cortex and muscarinic and serotonin 5-HT2-receptor bindings in rat cerebral cortex. The ability to penetrate into the CNS in mice was evalu ated from the inhibitory effect on histamine-induced in crease of peripheral vascular permeability in comparison to the ex vivo displacement of [3H]mepyramine binding to brain H1-receptors. For guinea pigs, the penetrative ability was evaluated by the ex vivo displacement of
[3H]mepyramine binding to H1-receptors in the cerebral cortex and the lung, one of the peripheral target organs of antiallergic agents. We also tried to elucidate whether the amphoteric chemical structure of HSR-609 is related to its selectivity for the H1-receptor and its ability to penetrate into the CNS by comparing its properties with those of the non-amphoteric basic compound PY-608 (8-fluoro 5,11-dihydro-l 1-(1-methyl-4-piperidylidene)benz [b] oxep ino [4, 3-b] pyridine), which has a chemical structure simi lar to that of HSR-609 (Fig. 1) . 
MATERIALS AND METHODS

Animals
Male ICR mice (Charles River Japan, Kanagawa), male Wistar rats (Japan SLC, Shizuoka) and male Hartley guinea pigs (Japan SLC) were used. The animals were fasted for more than 16 hr before oral administration of the test compounds.
Effect on in vitro binding assay of HI-receptors
The in vitro binding assay of Hi-receptors was per formed using the guinea pig cerebral cortex. Guinea pigs (6-week-old) were killed by decapitation, and the cerebral cortex was rapidly removed and homogenized by a Polytron (Kinematica, Luzern, Switzerland) in 20 vol. of ice-cold 50 mM sodium-potassium phosphate buffer (pH 7.4). The homogenate was centrifuged 2 times at 50,000 x g for 15 min at 41C using an ultracentrifuge (12) with some modifications. The binding reaction was initiated by mixing the buffer with test compound (0.4 ml), the radioligand (0.1 ml) and the final pellet suspension for each receptor (0.5 ml). The mixture was incubated with shaking at 25C for 120 min. The incubation was termi nated by adding 5 ml of ice-cold buffer, and the sample was rapidly filtered through a Whatman GF/B glass filter using a Cell Harvester (M-24R; Brandel, Geithersburg, MD, USA) and then washed 3 times with 5 ml of ice-cold buffer. The filters were dried and placed in 7 ml of Aquazol-2 (Dupont/NEN, Boston, MA, USA), and the radioactivity was measured with a liquid scintillation counter (1600TR; Packard, Meriden, CT, USA). The specific binding of radioligand was taken as the difference between the radioactivity bound in the absence or presence of 1 yM promethazine hydrochloride. The IC50 values (concentrations of test compounds producing 50% inhibition of specific binding of radioligand) were deter mined according to the EBDA ligand program (13) . The Kd (dissociation constant) values were calculated from Scatchard plots. The radioligand competition activities of test compounds were expressed as K; = IC50 / (1 + L / Kd), where L was the concentration of the radioligand used (14) . Negative logarithms of K; (pK1) values of the test compounds were determined.
Effect on in vitro binding assay of muscarinic and 5 HT2 -receptors
In vitro binding assays of muscarinic and 5-HT2-recep tors were performed using the rat cerebral cortex. Rats (6 to 10-week-old) were killed by decapitation and the cerebral cortex was rapidly removed and homogenized in 20 vol. of ice-cold buffer (for muscarinic receptor bind ing: 50 mM sodium-potassium phosphate buffer, pH 7.4; for 5-HT2-receptor binding: 50 mM Tris-hydrochloride buffer, pH 7.4). The homogenate was centrifuged 2 times at 50,000 x g for 15 min at 41C. The final membrane pellet was resuspended in 1200 vol. of ice-cold buffer for mus carinic receptor binding and in 100 vol. 
Effect on histamine-induced vascular increase of perme ability in mice
The test compounds were orally administered to 6 week-old mice in groups of 7-13 animals. After 1 hr, the mice were lightly anesthetized with ether. Immediately following an intravenous injection of 0.2 ml of 1 % Evans blue saline solution through the caudal vein, a cutaneous reaction was induced by intradermal injection of 25 pl/site of histamine dihydrochloride (0.1 mg/ml) into the depilated skin on the back. After 30 min, the mice were killed by cervical dislocation, the histamine injection site was isolated, and the intensity of the response was evaluated by the amount of extravasated dye according to the method of Katayama et al. (17) . The percentage of inhibition of the test compound was calculated by com parison with the mean responses of vehicle controls, while the ED50 values (doses of test compounds producing 50% inhibition of histamine-induced vascular permeability) and their 95% confidence limits were calculated from the number of animals showing more than 50% inhibition at each dose according to the Probit method of the Yukms Statistical Library (Yukms, Tokyo).
Effect on ex vivo [3H]mepyramine binding to HI-recep tors in the mouse brain
The test compounds were orally administered to 6 week-old mice in groups of 5 animals each. After 1 hr, the mice were killed by cervical dislocation, and the whole brains were immediately removed and homogenized in 40 vol. of ice-cold 50 mM sodium-potassium phosphate buffer (pH 7.4). The receptor-ligand binding assay was performed in duplicate using [3H]mepyramine (final con centration of 2 nM) by the method of Ahn and Barnett (12) with some minor modifications. The binding reaction was initiated by mixing the buffer (0.4 ml), the radio ligand (0.1 ml) and the brain homogenate suspension (0.5 ml). The mixture was incubated at 25C for 30 min with shaking. The following receptor-ligand binding assays were carried out by the above-described in vitro bind ing assay of H1-receptors. The ID50 values (doses of test compounds producing 50% inhibition of the specific bind ing of a radioligand) and their 95% confidence limits were calculated from the percentage of inhibition at each dose according to the method of Tallarida and Murray (18) .
Effect on ex vivo [3H]mepyramine binding to HI-recep tors in the cerebral cortex and the lung of guinea pigs
The test compounds were orally administered to 5 to 6-week-old guinea pigs in groups of 4 animals each. After 2 hr, the guinea pigs were killed by decapitation, and the cerebral cortex and the lung parenchyma were immedi ately removed and homogenized in 10 vol. of ice-cold 50 mM sodium-potassium phosphate buffer (pH 7.4). The lung homogenate was filtered through two layers of gauze. The homogenates were centrifuged 2 times at 50,000 x g for 15 min at 4C. The final membrane pellets were resuspended in 50 vol. of ice-cold buffer in the case of the cerebral cortex pellets or in 40 vol. of ice-cold buffer in the case of the lung pellets. The following receptor-ligand binding assay of ex vivo displacement of [3H]mepyramine binding was carried out in triplicate as described in the above method for the ex vivo [3H] mepyramine binding to H1-receptors in the mouse brain.
Drugs
The following agents were purchased: cyproheptadine 
RESULTS
Effect on in vitro binding assay of HI-, muscarinic and 5 HT2 -receptors With respect to the H1-receptor binding in the guinea pig cerebral cortex in vitro, HSR-609, PY-608 and typical antiallergic agents concentration-dependently inhibited the [3H]mepyramine binding to H1-receptors and dis
played high affinities for H1-receptors (pKi>7). Among these compounds, PY-608, cyproheptadine, ketotifen and azelastine showed much higher affinities for H1 receptors (pKi > 9) ( Table 1) .
As for the muscarinic receptor binding in the rat cerebral cortex in vitro, HSR-609 and cetirizine hardly affected the [3H]quinuclidinyl benzilate binding to the muscarinic receptors and had little affinity for these receptors (pKi < 5). In contrast, PY-608 and cyprohepta dine had high affinities for muscarinic receptors (pKi > 7); ketotifen, azelastine and oxatomide also showed moder ate affinities (7 > pKi > 6); and terfenadine displayed low affinity (6>pKi>5).
The ratio of the H1-receptor affinity to the muscarinic receptor affinity was calculated. The selectivity of HSR-609 for the H1-receptor was 690, which was lower than those of ketotifen (1200), azelastine (1000) and cetirizine (>2700), but higher than those of PY-608 (25), cyproheptadine (3.3), oxatomide (17) and terfena dine (45) ( Table 1) .
With the 5-HT2-receptor binding in the rat cerebral cortex in vitro, HSR-609 and cetirizine hardly affected the [3H]ketanserin binding to 5-HT2-receptors and had little affinity for 5-HT2-receptors (pKi < 5). In contrast, PY 608, cyproheptadine, ketotifen, azelastine and oxatomide had high affinities for 5-HT2-receptors (pKi > 7), while terfenadine displayed moderate affinity for 5-HT2-recep tors (7 > pKi > 6). The ratio between the H1-receptor affinity and the 5-HT2-receptor affinity was calculated. The selectivity of HSR-609 for the H1-receptor was 250, which was lower than that of cetirizine (740), similar to that of ketotifen (230), and higher than those of PY-608 (81), cyproheptadine (2.2), azelastine (110), oxatomide (0.49) and terfenadine (9.1) ( Table 1) .
Effect on histamine-induced increase of vascular perme ability in mice Extravasated dye was found at the injection site on the back with 2.5 pg histamine. The amount of extravasated dye in the control ranged from 9.0± 1.5 to 14.7:E1.3 pg/site among the experiments. Oral administration of HSR-609 at doses of 0.01-0.1 mg/kg produced dose dependent inhibition of the histamine-induced increase of vascular permeability. The inhibition of HSR-609 at doses of more than 0.03 mg/kg was statistically sig nificant. The ED50 value of HSR-609 was 0.021 mg/kg, and its potency was almost the same as those of PY-608 and cetirizine, but more than those of cyproheptadine, ketotifen, azelastine, oxatomide and terfenadine (Table  2) .
Effect on ex vivo [3HJmepyramine binding to HI-recep tors in mouse brain
Oral administration of HSR-609 at doses of 10 and 30 mg/kg produced dose-dependent inhibition of the [3H]mepyramine binding to H1-receptors in mouse brain ex vivo. The ID50 value of HSR-609 was 12 mg/kg, and its potency was less than those of PY-608, cyproheptadine, ketotifen, azelastine and cetirizine, but the same as that of oxatomide and more than that of terfenadine. The ID50 value of [3H]mepyramine binding to H1-receptors in mouse brain (B) was compared with the ED50 value of histamine-induced vascular permeability in mice (A). The ID50/ ED50 ratio (B/A) of HSR-609 was 570; and its value was much larger than those of PY-608 (2.4), cyprohepta dine (1.6), ketotifen (2.0), azelastine (3.6), oxatomide (4.1) and larger than those of terfenadine (160) and cetirizine (210) ( Table 2) .
Effect on ex vivo [3HJmepyramine binding to HI-recep tors in the cerebral cortex and lung of guinea pigs Oral administration of HSR-609 at doses of 0.1-10 mg/kg produced dose-dependent inhibition of the [3H] mepyramine binding to H 1-receptors in guinea pig lung ex vivo, and the inhibition at doses of more than 0.1 mg/kg was statistically significant. Oral administration of HSR 609 at doses of 10 and 100 mg/kg produced dose-de pendent inhibition of the [3H]mepyramine binding to H1-receptors in the cerebral cortex of guinea pigs ex vivo, and the inhibition at doses of more than 10 mg/kg was statistically significant. The minimum inhibitory dose of HSR-609 in the lung was 100 times less than that in the cerebral cortex. The dose ratio of HSR-609 was much larger than those of PY-608 (10) and ketotifen (1), but the same as that of terfenadine (100) (Fig. 2) . 
DISCUSSION
According to our previous basic studies on the relationship between chemical structure and pharma cological activity, zwitter-ionization of classical tricyclic antihistamines by introducing N-alkyl-carboxy groups instead of N-alkyl groups results in retention of the H1 receptor antagonistic activity, while greatly reducing other pharmacological activities such as antagonistic ac tivities toward muscarinic, serotonergic and a1-adrenergic receptors, affinities for a2-adrenergic and dopamine D2 receptors, and inhibitory effects on noradrenaline and serotonin uptakes (1). Our results from the in vitro bind ing assay also showed that the new zwitter-ionizated am photeric compound HSR-609 had low affinities for mus carinic and 5-HT2-receptors, but high affinities for H1 receptors. In contrast, the non-amphoteric basic com pound PY-608 displayed high affinities for H1-, muscar inic and 5-HT2-receptors and low selectivity for the H1 receptor in vitro. Therefore, these findings indicate that the amphoteric chemical structure of HSR-609 may play an important role in its high selectivity for the H1-recep tor.
Sedative and hypnotic effects in humans have been found with not only antihistamines, but also the muscar inic receptor antagonist scopolamine, and the 5-HT2 receptor antagonist ritanserin (11, 19, 20) . Therefore, it has been suggested that the sedative actions of classical antihistamines may be ascribed to other properties in cluding anticholinergic and antiserotonergic effects as well as antihistaminic effects (11) . Our results from the in vitro binding assay also showed that sedative antiallergic agents such as cyproheptadine and oxatomide displayed high affinities not only for H1-receptors, but also for muscarinic and/or 5-HT2-receptors. These findings indi cate that the depressant effects on the CNS of some seda tive antiallergic agents may arise from their effects on the muscarinic and/or 5-HT2-receptors as well as the H1 receptor. Terfenadine had moderate affinity for 5-HT2 receptors and low selectivity for the H1-receptor in vitro, in agreement with previous reports (11, 21) . Terfenadine was reported to undergo rapid and extensive biotransfor mation to a carboxylic acid derivative (active metabolite) and an amino derivative (inactive metabolite) in humans (22) . Its effects in vitro are not thought to directly reflect the in vivo effect. On the other hand, HSR-609 has been found to be hardly metabolized in rats and dogs, and its unchanged form is thought to be an active compound (unpublished data). Therefore, the selective effect of HSR-609 on the H1-receptor in vitro is thought to directly reflect the in vivo effect, and these findings suggest that HSR-609 is unlikely to produce clinical side effects such as sedation and dryness of the mouth, which are due to anti muscarinic and/or antiserotonergic effects. On the basis of the selectivity of HSR-609 for the H1 receptor in vitro, its ability to penetrate into the CNS was evaluated by the potency ratio between the inhibitory effect on histamine-induced increase of vascular permeability in mice (ED50) and the ex vivo displacement of [3H]mepyramine binding to H1-receptors in mouse brain (ID50). The ID50/ED50 ratios of cyproheptadine, ketotifen, azelastine and oxatomide were much smaller than those of terfenadine and cetirizine. Therefore, we checked for obvious differences in the abilities to pen etrate into the CNS in mice between sedative and non sedative antiallergic agents having antihistaminic activ ities by using ex vivo displacement of [3H]mepyramine binding in comparison to the peripheral antihistaminic effect. The ratio of HSR-609 was much larger than those of sedative antiallergic agents and larger than those of non-sedative antiallergic agents. These results indicate that the ability of HSR-609 to penetrate into the CNS in mice is much lower than those of sedative antiallergic agents and lower than those of non-sedative antiallergic agents. Furthermore, the ability of HSR-609 to penetrate into the CNS in guinea pigs was evaluated by the ex vivo dis placement of [3H]mepyramine binding to H1-receptors in the cerebral cortex and the lung. HSR-609 displayed po tent displacement of the binding in the lung at much low er doses than those in the cerebral cortex. The peripheral tissue selectivity of HSR-609 was higher than that of ketotifen and similar to that of terfenadine. These results indicate that there is little difference in the penetrative ability of a sedative antiallergic agent between the peripheral tissue and the CNS in guinea pigs. However, the ability of HSR-609 and a non-sedative antiallergic agent to penetrate into the CNS was lower than that into the peripheral tissue. Leysen et al. (21) also showed, using ex vivo displacement of [3H]mepyramine binding in guinea pigs, that terfenadine seems to have the ability of selective penetration into the lung in comparison to the cerebellum, similar to our results. However, according to their results, terfenadine at a dose of 10 mg/kg showed much more penetration into the cerebellum compared with our findings. This may have been due to differences in strain, sex and tissue of guinea pigs or other ex perimental conditions. Leysen et al. used the cerebellum of female Pirbright guinea pigs, while we used the cerebral cortex of male Hartley guinea pigs.
The antihistaminic activity of the non-amphoteric basic compound PY-608 on histamine-induced increase of vas cular permeability in mice was as potent as that of HSR 609. However, the penetrative abilities of PY-608 into the CNS in mice and guinea pigs ex vivo were much higher than those of HSR-609. Therefore, these results indicate that the amphoteric chemical structure of HSR-609 may be an important factor in reducing the penetration into the CNS.
In conclusion, the pharmacological differences be tween sedative and non-sedative antiallergic agents can be clearly evaluated by determining their abilities to pene trate into the CNS, using ex vivo displacement of [3H] mepyramine binding to H1-receptors in the brain and peripheral tissue of mice and guinea pigs. HSR-609 ap pears to have high selectivity for the H1-receptor, but poor ability to penetrate into the CNS, which may be due to its amphoteric chemical structure. These findings sug gest that HSR-609 can be an antiallergic agent having few depressant effects on the CNS such as sedation.
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